Denali Therapeutics Stock Current Ratio
| DNLI Stock | USD 15.99 0.01 0.06% |
Denali Therapeutics fundamentals help investors to digest information that contributes to Denali Therapeutics' financial success or failures. It also enables traders to predict the movement of Denali Stock. The fundamental analysis module provides a way to measure Denali Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Denali Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 13.65 | 15.07 |
Denali | Current Ratio |
Denali Therapeutics Company Current Ratio Analysis
Denali Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Denali Therapeutics Current Ratio | 3.20 X |
Most of Denali Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Denali Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Denali Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Denali Therapeutics is extremely important. It helps to project a fair market value of Denali Stock properly, considering its historical fundamentals such as Current Ratio. Since Denali Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Denali Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Denali Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Denali Current Ratio Historical Pattern
Today, most investors in Denali Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Denali Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Denali Therapeutics current ratio as a starting point in their analysis.
Denali Therapeutics Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Denali Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Denali Therapeutics has a Current Ratio of 3.2 times. This is 9.97% higher than that of the Biotechnology sector and 54.29% lower than that of the Health Care industry. The current ratio for all United States stocks is 48.15% lower than that of the firm.
Denali Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Denali Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics of similar companies.Denali Therapeutics is currently under evaluation in current ratio category among related companies.
Denali Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Denali Therapeutics from analyzing Denali Therapeutics' financial statements. These drivers represent accounts that assess Denali Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Denali Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.9B | 1.7B | 9.1B | 3.5B | 2.9B | 2.2B | |
| Enterprise Value | 1.8B | 1.7B | 8.7B | 3.3B | 2.9B | 2.1B |
Denali Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0941 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 1.24 B | ||||
| Shares Outstanding | 142.54 M | ||||
| Shares Owned By Insiders | 13.78 % | ||||
| Shares Owned By Institutions | 79.57 % | ||||
| Number Of Shares Shorted | 9.41 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 7.69 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (250.27 M) | ||||
| EBITDA | (179.97 M) | ||||
| Net Income | (145.22 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 52.24 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 7.45 X | ||||
| Cash Flow From Operations | (357.99 M) | ||||
| Short Ratio | 7.82 X | ||||
| Earnings Per Share | (1.06) X | ||||
| Target Price | 41.19 | ||||
| Number Of Employees | 445 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 2.28 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 986.15 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
| Net Asset | 1.15 B |
About Denali Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Denali Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Denali Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Denali Therapeutics' short interest history, or implied volatility extrapolated from Denali Therapeutics options trading.
Pair Trading with Denali Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Denali Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Denali Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Denali Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Denali Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Denali Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Denali Therapeutics to buy it.
The correlation of Denali Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Denali Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Denali Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Denali Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Denali Therapeutics Piotroski F Score and Denali Therapeutics Altman Z Score analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.06) | Revenue Per Share 2.406 | Quarterly Revenue Growth (1.00) | Return On Assets (0.09) | Return On Equity (0.14) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.